MAK Scientific LLC — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2015, MAK Scientific operates as a boutique scientific services firm, leveraging deep expertise in small molecule drug discovery to support client R&D programs. The company's business model is based on providing high-level consulting and hands-on contract research, acting as an extension of its clients' internal teams. It serves a global clientele of biopharma companies, from startups to established players, helping to de-risk and accelerate early-stage projects. As a private services company, its financial position is tied to project-based contracts and consulting engagements.

Small Molecules

Technology Platform

Integrated expertise in medicinal and computational chemistry, including structure-based drug design, virtual screening, lead optimization, and strategic project leadership for small molecule discovery.

Opportunities

Growing demand for specialized small molecule expertise from virtual and small biotech firms.

Increased outsourcing of core discovery functions by large pharma to improve R&D efficiency.

Opportunity to form deep, strategic partnerships with clients on long-term programs.

Risk Factors

Revenue vulnerability due to client concentration and cyclical biotech funding.

Intense competition from large CROs and other boutique consultants.

Dependence on retaining a small team of highly specialized scientific talent.

Competitive Landscape

MAK Scientific competes in a fragmented market including large global CROs (e.g., LabCorp, IQVIA), specialized chemistry CROs, and individual consultant networks. Its differentiation lies in offering senior-level, strategic consulting combined with hands-on research, positioning it as a premium boutique service rather than a high-volume provider.

More companies in United States →